Latest Corporate News
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Thera...
Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
Collaboration Leverages the OPTF01 product to Drive Next-Generation CA...
Cellipont Bioservices Appoints Brett Reynolds as Chief Financial Officer to Lead Financial Strategy and Support Growth in Cell Therapy CDMO Sector
Cellipont Bioservices, a leading cell therapy Contract Development and...
Press Inquiry? Send us a message
